Analyst Price Target is $38.00
▲ +1.71% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Translate Bio in the last 3 months. The average price target is $38.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1.71% upside from the last price of $37.36.
Current Consensus is
The current consensus among 4 polled investment analysts is to hold stock in Translate Bio. This rating has held steady since March 2021, when it changed from a Buy consensus rating.
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.